MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
4.650
-0.110
-2.31%
After Hours: 4.650 0 0.00% 16:46 12/05 EST
OPEN
4.750
PREV CLOSE
4.760
HIGH
4.880
LOW
4.565
VOLUME
1.07M
TURNOVER
0
52 WEEK HIGH
18.31
52 WEEK LOW
2.830
MARKET CAP
441.19M
P/E (TTM)
-1.8808
1D
5D
1M
3M
1Y
5Y
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
THOUSAND OAKS, Calif., November 23, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer an...
Business Wire · 11/23 13:00
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Benzinga · 11/11 10:10
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Benzinga · 11/10 10:12
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 22:15
Atara Biotherapeutics Q3 EPS $(0.82) Misses $(0.78) Estimate, Sales $4.46M Miss $5.27M Estimate
Benzinga · 11/08 21:26
BRIEF-Atara Biotherapeutics Announces Third Quarter 2022 Financial Results, Operational Progress
Reuters · 11/08 21:19
Atara Biotherapeutics GAAP EPS of -$0.82 misses by $0.03, revenue of $4.46M beats by $0.72M
Seekingalpha · 11/08 21:03
Atara Biotherapeutics Q3 2022 Earnings Preview
Seekingalpha · 11/07 22:35
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.